Manipal Health Enterprises LimitedPharmaceuticals & HealthcareMANIPALHOS
Q1 FY27 earnings callManipal Health Enterprises Limited
Manipal Hospitals delivered strong growth in its first quarter as a public company, driven by patient demand, high-acuity specialty care, and the integration of Sahyadri Hospitals.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue from Operations | ₹ 3,091 crore | 38.1% | |
| EBITDA | ₹ 749 crore | 26.4% | |
| PAT | ₹ 243 crore | -4.2% | |
| Occupancy % | 65.0% | 290 bps | |
| ARPOB (Excluding Sahyadri) | ₹ 77,200 per day | 8.7% | |
| Inpatient Volumes | 155k | 38.8% |
TL;DR
- Revenue grew 38.1% year-on-year to ₹3,091 crore.
- EBITDA grew 26.4% to ₹749 crore (29.7% excluding a one-off gain in the prior year).
- Adjusted PAT, excluding interest on the Sahyadri acquisition NCD, grew 30.9%.
- Inpatient volumes grew 38.8% and occupancy improved by 290 basis points to 65.0%.
- The CONGO-R specialty mix increased to 65.4% of inpatient revenue.
- Sahyadri Hospitals contributed revenue of ₹332 crore with 12.8% year-on-year growth.
Said on the call
“Our performance this quarter reflects the strength of our Pan-India network, sustained patient demand and continued growth in high-acuity specialties.”
Guidance
- The integration of Sahyadri Hospitals remains a key priority to unlock benefits of a larger network and greater operating scale.
- The IPO provides greater flexibility to invest in capacity, technology and clinical excellence while maintaining disciplined capital allocation.
- Remain focused on expanding access, strengthening clinical outcomes, improving efficiency and building a more integrated and sustainable healthcare platform.
Source
Summary written from the transcript filed by Manipal Health Enterprises Limited for the call held on 21 Aug 2026; published 20 Aug 2026, 19:58 IST.